查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403510

2030 年人類血小板裂解物市場預測：按藥物類型、給藥途徑、配銷通路、最終用戶和地區進行的全球分析

Human Platelet Lysate Market Forecasts to 2030 - Global Analysis By Drug Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球人血小板裂解物市場規模為 5,375 萬美元，預計到 2030 年將達到 8,029 萬美元，預測期內複合年成長率為 5.9%。

人類血小板裂解物 (HPL) 是一種源自人類血小板的細胞培養補充品。含有血小板衍生生長因子（PDGF）、轉化生長因子BETA（TGF-B）和類胰島素生長因子（IGF）等生長因子，以及促進細胞存活和刺激組織再生的各種蛋白質。此外，與牛(FBS) 等傳統細胞培養補充品相比，它具有許多優勢。 HPL 需求不斷成長是由於多種促進因素​​，包括其安全性、效率和道德考慮。

美國國家醫學圖書館發布的資料表明，人類血小板裂解物 (hPL) 的製造成本比牛更昂貴，而胎牛血清是人類血小板裂解物 (hPL) 的替代選擇。

對細胞培養應用的需求不斷成長

人類血小板裂解物因富含細胞生長和增殖所必需的生長因子和細胞激素而聞名，已成為傳統血清培養基的絕佳替代品。它支持細胞增殖、維持細胞特性和促進組織再生的能力使其在再生醫學、幹細胞研究和組織工程中越來越多的採用。此外，對個人化醫療、基於細胞的治療方法的日益關注以及基於細胞培養的藥物研發發現的進步進一步增加了對人類血小板裂解物的需求。因此，將促進市場的成長。

製造成本高

人類血小板裂解物經歷了複雜的製造過程，包括收集、處理和品管，導致與傳統的基於血清的培養基相比，製造成本更高。如此高的成本限制了細胞培養應用中廣泛商業性用途的承受能力和可用性，並可能阻礙其採用。結果，市場擴張受到阻礙。

再生醫學的進展

人類血小板裂解物富含細胞增生和組織再生必需的生長因子和細胞激素，完美滿足再生治療的要求。隨著再生醫學的不斷發展，HPL 已成為細胞培養中的重要輔助劑，可支持細胞增殖並維持組織再生所需的細胞特性。此外，其促進創傷治療、刺激組織修復和幫助開發基於細胞的治療方法的能力使人類血小板裂解物成為再生醫學應用中的寶貴成分。

污染風險

儘管與牛(FBS) 相比，異種污染減少，但人類血小板裂解物具有人源產品傳播病原體的潛在風險。細菌和病毒等污染物可能會損害人類血小板裂解物的品質和安全性，影響其在研究和臨床環境中細胞培養應用的適用性。因此，這是市場拓展的主要障礙。

COVID-19 的影響

COVID-19 大流行最初造成了醫療保健行業的混亂和捐血限制，影響了 HPL 製造的原料的可得性。供應鏈中斷和實驗室活動減少擾亂了 HPL 的製造和分銷。然而，這場大流行凸顯了基於細胞的療法的重要性，並增加了人們對 HPL 發揮關鍵作用的再生醫學和細胞培養應用的興趣。隨著醫療保健產業的適應，隨著細胞治療方法研究重點的增加，市場已經捲土重來，這可能會進一步推動對 HPL 的需求。

預計基於肝素的人類血小板裂解物部分在預測期內將是最大的

據估計，基於肝素的人類血小板裂解物部分佔最大佔有率。肝素用於防止血小板採集和 HPL 製造過程中發生凝血，確保維持血小板完整性和生物活性。這種專門的 HPL 透過支持細胞生長、增殖和活力，為細胞培養應用帶來好處。肝素配方可增強 HPL 功能，特別有益於各種生物醫學領域，例如再生醫學、幹細胞研究和組織工程，在這些領域中，維持血小板生物活性對於獲得最佳細胞培養結果至關重要。

醫院藥房業務預計在預測期內複合年成長率最高

預計醫院藥局業務在預測期內將出現良好成長。醫院藥局是向醫療機構、臨床醫生和研究人員提供人類血小板溶解產品的重要中介機構。這些藥房在為再生醫學、細胞治療和研究等各種醫療應用提供人類血小板裂解物方面發揮著至關重要的作用。此外，這些藥房確保人類血小板裂解物產品的可用性、品質和及時分發，促進其在臨床環境和醫院實驗室中的使用。

比最大的地區

由於生物醫學研究活動的活性化、再生醫學投資的增加以及對細胞療法的日益關注，亞太地區在預測期內佔據了最大的市場佔有率。中國、日本、韓國和印度等國家透過利用醫療基礎設施和研究舉措的進步，為 HPL 市場的成長做出了重大貢獻。此外，該地區蓬勃發展的生物製藥產業，加上其對個人化醫療和再生療法的關注，為HPL的採用提供了重要的機會，使亞太地區成為HPL在多種生物醫學應用中應用的重要場所。 。

複合年成長率最高的地區：

由於先進的醫療基礎設施、強勁的生物製藥行業以及對生物醫學研究的大量投資，預計北美在預測期內將實現盈利成長。對個人化醫療的重視和對細胞療法日益成長的需求正在推動 HPL 在各種生物醫學應用中的使用。此外，北美已成為以尖端研發為特徵的關鍵地區，並為 HPL 在生物醫學研究和臨床環境中廣泛採用奠定了堅實的基礎。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球人類血小板裂解物市場：依藥物類型

  • 基於肝素的人類血小板裂解物
  • 無肝素人血小板裂解物
  • 其他類型

第6章全球人類血小板裂解物市場：依給藥途徑

  • 口服
  • 用於吸入
  • 其他給藥途徑

第7章全球人血小板裂解物市場：按配銷通路

  • 醫院藥房
  • 藥局
  • 零售店
  • 網路藥房

第8章全球人類血小板裂解物市場：依最終用戶分類

  • 治療性的
  • 研究/學術機構
  • 製藥和生物技術公司
  • 其他最終用戶

第9章全球人類血小板裂解物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Abbott Laboratories
  • Astrazeneca Plc.
  • Acella Pharmaceuticals LLC
  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • Dabur India Ltd
  • Johnson and Johnson
  • Glenmark Pharmaceuticals Limited
  • Merck KGaA
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi SA
  • Vernalis plc
  • Aurobindo Pharma Ltd
  • The Himalaya Drug Company
  • Beckman Coulter Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group PLC
  • Acadia Pharmaceuticals Inc.
  • Biocon
Product Code: SMRC24735

According to Stratistics MRC, the Global Human Platelet Lysate Market is accounted for $53.75 million in 2023 and is expected to reach $80.29 million by 2030 growing at a CAGR of 5.9% during the forecast period. Human Platelet Lysate (HPL) is a cell culture supplement derived from human blood platelets. It contains growth factors like platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-B), insulin-like growth factor (IGF), and various other proteins that promote cell survival and stimulate tissue regeneration. Moreover, it offers numerous advantages over traditional cell culture supplements like foetal bovine serum (FBS). The growing demand for HPL can be attributed to several driving factors, including its safety, efficiency, and ethical considerations.

According to data published on National Library of Medicine, stated that human platelet lysate (hPL) has higher production cost than foetal bovine serum, which is an alternative option of human platelet lysate (hPL).

Market Dynamics:

Driver:

Increasing demand in cell culture applications

Human platelet lysate, renowned for its rich composition of growth factors and cytokines essential for cell growth and proliferation, has emerged as a superior alternative to traditional serum-based media. Its ability to support cell expansion, maintain cellular properties, and promote tissue regeneration has led to increased adoption in regenerative medicine, stem cell research, and tissue engineering. Moreover, the heightened focus on personalised medicine, cell-based therapies, and advancements in drug discovery utilising cell cultures further amplifies the need for human platelet lysate. Therefore, it will propel market growth.

Restraint:

High production costs

The complex manufacturing process involving the collection, processing, and quality control measures for human platelet lysate results in elevated production expenses compared to traditional serum-based media. These higher costs limit its affordability and accessibility for widespread commercial use in cell culture applications, potentially hindering its adoption. As a result, it will hamper market expansion.

Opportunity:

Advancements in regenerative medicine

The human platelet lysate's rich composition of growth factors and cytokines essential for cell growth and tissue regeneration aligns perfectly with the requirements of regenerative therapies. As regenerative medicine continues to evolve, HPL emerges as a crucial supplement in cell culture, supporting cell proliferation and maintaining cellular properties necessary for tissue regeneration. Furthermore, its ability to enhance wound healing, stimulate tissue repair, and aid in the development of cell-based therapies positions human platelet lysate as a valuable component in regenerative medicine applications.

Threat:

Contamination risks

Despite reduced xenogeneic contamination compared to foetal bovine serum (FBS), human platelet lysate carries the potential risk of pathogen transmission from human-derived products. Contaminants, such as bacteria or viruses, could compromise the quality and safety of human platelet lysate, impacting its suitability for cell culture applications in research and clinical settings. Hence, it acts as a significant barrier to market expansion.

COVID-19 Impact

The COVID-19 pandemic initially caused disruptions in the healthcare sector and restrictions on blood donations, which affected the availability of raw materials for HPL production. Supply chain disruptions and reduced laboratory activities hindered its manufacturing and distribution. However, the pandemic underscored the importance of cell-based therapies, boosting interest in regenerative medicine and cell culture applications where HPL plays a crucial role. As the healthcare sector adapted, the market witnessed a resurgence due to increased research focus on cell-based treatments, potentially driving further demand for HPL.

The heparin-based human platelet lysate segment is expected to be the largest during the forecast period

The heparin-based human platelet lysate segment is estimated to hold the largest share. Heparin serves to prevent clotting during platelet collection and HPL production, ensuring the maintenance of platelet integrity and bioactivity. This specialised variant of HPL offers advantages in cell culture applications by supporting cell growth, proliferation, and viability. The inclusion of heparin enhances the functionality of HPL, making it particularly beneficial in various biomedical fields, including regenerative medicine, stem cell research, and tissue engineering, where uninterrupted platelet bioactivity is essential for optimal cell culture outcomes.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to have lucrative growth during the forecast period. Hospital pharmacies serve as crucial intermediaries, providing human platelet lysate products to healthcare facilities, clinicians, and researchers. These pharmacies play a pivotal role in supplying human platelet lysate for various medical applications, including regenerative medicine, cell therapy, and research endeavours. Moreover, they ensure the availability, quality, and timely distribution of human platelet lysate products, facilitating their use in clinical settings and research laboratories within hospitals.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising biomedical research activities, increasing investments in regenerative medicine, and a growing focus on cell-based therapies. Countries such as China, Japan, South Korea, and India are prominent contributors to HPL market growth, leveraging advancements in healthcare infrastructure and research initiatives. Furthermore, the region's burgeoning biopharmaceutical industry, combined with the emphasis on personalised medicine and regenerative therapies, offers substantial opportunities for HPL adoption, shaping the Asia-Pacific region as a significant hub for HPL utilisation in diverse biomedical applications.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to advanced healthcare infrastructure, a robust biopharmaceutical industry, and substantial investments in biomedical research. Growing emphasis on personalised medicine and the escalating demand for cell-based therapies bolster the utilisation of HPL in various biomedical applications. Furthermore, North America stands as a key region, characterised by its cutting-edge developments and a strong foundation for the widespread adoption of HPL in biomedical research and clinical settings.

Key players in the market:

Some of the key players in the Human Platelet Lysate Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Glenmark Pharmaceuticals Limited, Dabur India Ltd, Johnson and Johnson, Glenmark Pharmaceuticals Limited, Merck KGaA, Pfizer Inc., Novartis International AG, Sanofi SA, Vernalis plc, Aurobindo Pharma Ltd, The Himalaya Drug Company, Beckman Coulter Inc., Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC, Acadia Pharmaceuticals Inc. and Biocon.

Key Developments:

In June 2023, PL BioScience GmbH entered into a Patent License and Assignment Agreement with French company Macopharma S.A.S., granting PL BioScience a worldwide license under Macopharma's patents and introducing PL BioScience to Macopharma's HPL customers for future orders.

In August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.

In June 2021, Captivate Bio has signed a partnership agreement with PL BioScience GmbH to exclusively distribute ELAREM human platelet lysate products in the US and Canada, expanding their HPL offerings and enhancing PL BioScience's market presence in North America.

Drug Types Covered:

  • Heparin-based Human Platelet Lysate
  • Heparin-free Human Platelet Lysate
  • Other Types

Route of Administrations Covered:

  • Oral
  • Inhalational
  • Other Routes of Administration

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Store
  • Retail Store
  • Online Pharmacies

End Users Covered:

  • Therapeutic
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Platelet Lysate Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Heparin-based Human Platelet Lysate
  • 5.3 Heparin-free Human Platelet Lysate
  • 5.4 Other Types

6 Global Human Platelet Lysate Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Inhalational
  • 6.4 Other Routes of Administration

7 Global Human Platelet Lysate Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Drug Store
  • 7.4 Retail Store
  • 7.5 Online Pharmacies

8 Global Human Platelet Lysate Market, By End User

  • 8.1 Introduction
  • 8.2 Therapeutic
  • 8.3 Research and Academic Institutions
  • 8.4 Pharmaceutical and Biotechnology Companies
  • 8.5 Other End Users

9 Global Human Platelet Lysate Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 Astrazeneca Plc.
  • 11.3 Acella Pharmaceuticals LLC
  • 11.4 Cipla Limited
  • 11.5 Glenmark Pharmaceuticals Limited
  • 11.6 Dabur India Ltd
  • 11.7 Johnson and Johnson
  • 11.8 Glenmark Pharmaceuticals Limited
  • 11.9 Merck KGaA
  • 11.10 Pfizer Inc.
  • 11.11 Novartis International AG
  • 11.12 Sanofi SA
  • 11.13 Vernalis plc
  • 11.14 Aurobindo Pharma Ltd
  • 11.15 The Himalaya Drug Company
  • 11.16 Beckman Coulter Inc.
  • 11.17 Sun Pharmaceutical Industries Ltd.
  • 11.18 Reckitt Benckiser Group PLC
  • 11.19 Acadia Pharmaceuticals Inc.
  • 11.20 Biocon

List of Tables

  • Table 1 Global Human Platelet Lysate Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 4 Global Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 5 Global Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 6 Global Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 7 Global Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 8 Global Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 9 Global Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 10 Global Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 11 Global Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 12 Global Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 13 Global Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 14 Global Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 15 Global Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 16 Global Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 17 Global Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 18 Global Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 19 Global Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 22 North America Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 23 North America Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 24 North America Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 25 North America Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 26 North America Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 27 North America Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 28 North America Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 29 North America Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 North America Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 31 North America Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 32 North America Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 33 North America Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 North America Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 North America Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 36 North America Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 37 North America Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 38 North America Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 41 Europe Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 42 Europe Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 43 Europe Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 44 Europe Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 45 Europe Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 46 Europe Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 47 Europe Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 48 Europe Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 49 Europe Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 50 Europe Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 51 Europe Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 52 Europe Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 53 Europe Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Europe Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 55 Europe Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 56 Europe Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 57 Europe Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 61 Asia Pacific Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 62 Asia Pacific Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 63 Asia Pacific Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 64 Asia Pacific Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 65 Asia Pacific Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 66 Asia Pacific Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 67 Asia Pacific Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 68 Asia Pacific Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 69 Asia Pacific Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 79 South America Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 80 South America Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 81 South America Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 82 South America Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 83 South America Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 84 South America Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 85 South America Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 86 South America Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 87 South America Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 88 South America Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 89 South America Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 90 South America Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 91 South America Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 South America Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 93 South America Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 94 South America Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 95 South America Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
  • Table 99 Middle East & Africa Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
  • Table 100 Middle East & Africa Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 101 Middle East & Africa Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 102 Middle East & Africa Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
  • Table 103 Middle East & Africa Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 104 Middle East & Africa Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
  • Table 105 Middle East & Africa Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 106 Middle East & Africa Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 107 Middle East & Africa Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 108 Middle East & Africa Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 109 Middle East & Africa Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 110 Middle East & Africa Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
  • Table 111 Middle East & Africa Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
  • Table 112 Middle East & Africa Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
  • Table 113 Middle East & Africa Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)